ALF-ONE : ALFuzosin ONcE Daily
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the
 safety profile and the efficacy of a new formulation of alfuzosin administered once daily in
 patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia
 (BPH).
Inclusion Criteria:

 -  Ambulatory patients suffering from Lower Urinary Tract Symptoms suggestive of Benign
 Prostatic Hyperplasia

 Exclusion Criteria:

 -  Patients requiring Benign Prostatic Hyperplasia surgery immediately or within the 12
 following months

 -  Patients previously not improved by an alpha 1-blocker treatment

 -  Patients whose urinary symptoms are satisfactorily controlled on other Benign
 Prostatic Hyperplasia medication (alpha 1-blockers and 5-ARI)

 -  Known hypersensitivity to alfuzosin

 -  History of postural hypotension or syncope

 -  Combination with other alpha 1-blockers

 -  Hepatic insufficiency

 -  Unstable angina pectoris

 -  Severe concomitant condition threatening life